This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Cardiac troponin T and CRP: long-term mortality

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Lindahl B. et al followed up 917 patients who presented initially with unstable coronary artery disease. The mean follow up was period was 37 months. Levels of CRP, fibrinogen and maximal cardiac troponin T (cTnT) were measured during the first 24 hours.

Results showed:

  • 1.2% cardiac deaths for cTnT levels < 0.06 ug/l
  • 8.7% cardiac deaths for 0.06 ug/l < cTnT < 0.59 ug/l
  • 15.4% cardiac deaths for cTnT > 0.60 ug/l

  • 5.7% cardiac deaths for CRP <2mg/l
  • 7.8% cardiac deaths for 2mg/l < CRP < 10mg/l
  • 16.5% cardiac deaths for CRP > 10mg/l

Cardiac troponin T and CRP were found to be independent risk factors for death from a cardiac cause and their effects were shown to be additive.

Reference:

  • Lindahl B. et al. Markers of myocardial damage and inflammation inrelation to long-term mortality in unstable coronary artery disease. NEJM 2000;343(16):1139-1147.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.